Session Information
Date: Monday, June 5, 2017
Session Title: Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus)
Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: The International Parkinson and Movement Disorders Society-endorsed PSP Study Group aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for PSP.
Background: Progressive supranuclear palsy (PSP) is a neuropathologically defined disease entity. The NINDS-SPSP clinical diagnostic criteria, published in 1996, have excellent specificity, but their sensitivity is limited for variant PSP syndromes (vPSP) with presentations other than Richardson’s syndrome.
Methods: We searched the PubMed, Cochrane, Medline, and PSYCInfo databases for articles published in English since 1996, using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard. Secondly, we generated retrospective standardized clinical data from patients with autopsy-confirmed PSP, CBD, MSA-P, PD and FTLD-bvFTD. On this basis, diagnostic criteria were drafted, optimized in two modified Delphi evaluations, submitted to structured discussions with consensus procedures during a two-day meeting, and refined in three further Delphi rounds.
Results: Defined clinical, imaging, laboratory, and genetic findings serve as mandatory basic features, mandatory exclusion criteria or context-dependent exclusion criteria. We identified four functional domains (ocular motor dysfunction, postural instability, akinesia, cognitive dysfunction) as clinical predictors of PSP. Within each of these domains, we propose three clinical features that contribute different levels of diagnostic certainty. Specific combinations of these features define the diagnostic criteria, stratified by three degrees of diagnostic certainty (probable PSP, possible PSP, suggestive of PSP). Clinical clues and imaging findings represent supportive features.
Conclusions: Here, we present new criteria for the early, sensitive and specific clinical diagnosis of PSP on the basis of currently available evidence.
To cite this abstract in AMA style:
G. Höglinger, G. Respondek, M. Stamelou, C. Kurz, K. Josephs, A. Lang, B. Mollenhauer, U. Müller, C. Nilsson, J. Whitwell, A. Boxer, L. Golbe, I. Litvan. Movement Disorder Society – Clinical Diagnostic Criteria for Progressive Supranuclear Palsy [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/movement-disorder-society-clinical-diagnostic-criteria-for-progressive-supranuclear-palsy/. Accessed June 14, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/movement-disorder-society-clinical-diagnostic-criteria-for-progressive-supranuclear-palsy/